Beijing Wantai Biological Pharmacy Enterprise Co. Ltd.SSE: 603392

(603392)"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Receipt of the Clinical Trial Approval Notice for the Company's Lyophilized Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

· Issued by Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 603392 · · 2 pages · Chinese

Summary by 6ix AI

Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. announced that its subsidiary has received approval for clinical trials of a new vaccine. The vaccine is designed to prevent lower respiratory tract diseases caused by respiratory syncytial virus in older adults. The company highlighted the potential risks and competition in the vaccine market, emphasizing the lengthy approval process. Investors are advised to be cautious and stay informed about the project's progress.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/603392beijing-wantai-biological-pharmacy-enterprise-co-ltdannouncement-on-receipt-of-the-clinical-trial-approval-notice-for-the-companys-lyophilized-recombinant-respiratory-syncytial-virus-vaccine-cho-cells

Release

Announcement on Receipt of the Clinical Trial Approval Notice for the Company's Lyophilized Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. on 6ix

Story so far

Earlier from Beijing Wantai Biological Pharmacy Enterprise

All Beijing Wantai Biological Pharmacy Enterprise news releases